<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479518</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI06-IB Cohorte ABC-AVC</org_study_id>
    <nct_id>NCT00479518</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack</brief_title>
  <acronym>ABC-AVC</acronym>
  <official_title>Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with stroke or transient ischemic attack (TIA) are at high risk of poor outcome,
      recurrence of cardiovascular events or vascular death.Until now, no reliable predictive
      biological marker could be identified in the acute phase of stroke.We hypothese that, in the
      acute phase of ischemic stroke or TIA, the increase of cardiac ( brain natriuretic peptide,
      BNP) or renal markers (albuminuria, cystatin C)might predict recurrence of cardiovascular
      events or vascular death. We want to assess which one of these markers has the best prognosis
      value , in a prospective study of 300 stroke patients followed during 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of
      symptoms, in 3 university hospitals.For each patient will be collected

        -  1 blood sample for the BNP measure in pg/ml

        -  1 blood sample for the Cystatin C measure in mg/l

        -  2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days
           after the inclusion, and to study the variation of albuminuria in micrograms/min.

      The clinical follow-up will be organized during 3 years. The following events will be
      notified: poor outcome (defined with the Barthel and Rankin scores), recurrence of
      cardiovascular or cerebrovascular events, vascular death.

      After adjustment on the main clinical prognosis factors, we want to determine wich one of
      these markers has the best prognosis significance and allows to identify in the acute phase
      the &quot;high-risk&quot; patients, in order to intensify individual treatment and secondary
      prevention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2007</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">159</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Ischemic stroke or TIA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke or TIA in the first 48 hours following the onset of symptoms

        Exclusion Criteria:

          -  Patient unable to give an informed consent

          -  Urinary sample impossible to collect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BONNAUD Isabelle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Neurologie / CHRU de Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Neurologie / Hopital LAENNEC</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de neurologie / CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie / CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>albuminuria</keyword>
  <keyword>BNP</keyword>
  <keyword>Cystatin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

